The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

Kroot, E. J. A.; Jong, B.A.W. de; Leeuwen, M.A. van; Swinkels, H.L.; Hoogen, F.H.J. van den; Hof, M.A. van ‘t; Putte, L.B.A. van de; Rijswijk, M.H. van; Venrooij, W.J.W. van; Riel, P.L.C.M. van

doi:10.1002/1529-0131(200008)43:8<1831::aid-anr19>3.0.co;2-6

Cited by 546 publications

(344 citation statements)

References 15 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…However, the actual classification impact achieved using AKA compared with using rheumatoid factor as the sole laboratory criterion was very modest, mainly because the criteria were strongly interrelated. A similar study by Kroot and colleagues (20) using an anti-CCP ELISA found that almost 70% of RA patients were positive for anti-CCP in early RA and they had more radiologic damage. However, multiple regression analyses demonstrated that the additional predictive value given by anti-CCP ELISAs was only moderate (20).…”

mentioning

confidence: 70%

“…A similar study by Kroot and colleagues (20) using an anti-CCP ELISA found that almost 70% of RA patients were positive for anti-CCP in early RA and they had more radiologic damage. However, multiple regression analyses demonstrated that the additional predictive value given by anti-CCP ELISAs was only moderate (20). Another report, by Van Jaarsveld et al (21), evaluated the clinical value of the anti-CCP ELISA in combination with rheumatoid factor status in 249 patients with early RA.…”

mentioning

confidence: 70%

See 1 more Smart Citation

The diagnosis and prognosis of early arthritis: Rationale for new prognostic criteria

Scott

2002

Arthritis & Rheumatism

View full text Add to dashboard Cite

mentioning

confidence: 70%

mentioning

confidence: 70%

The diagnosis and prognosis of early arthritis: Rationale for new prognostic criteria

Scott

2002

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…Their cause and role remain unclear despite intense research [3]. Antibodies towards epitopes on arginine-rich proteins modified through citrullination occur frequently in RA and are today becoming one of the best diagnostic factors [4,5], although their cause and role are again still unclear [6,7]. Autoantibodies towards joint components, like type II collagen (CII) are also known to occur, but only in a minority of RA cases [8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis

et al. 2004

View full text Add to dashboard Cite

To analyze the role of the classical and alternative pathways of complement activation in the effector phase of arthritis, we have induced arthritis in C3-and factor B (FB)-deficient (C3 -/-and FB -/-) DBA/1J mice using well-defined monoclonal IgG2b and IgG2a antibodies to type II collagen. In control DBA/1J mice, severe swelling of the joints, destruction of cartilage and erosion of bone developed very rapidly with a 100% incidence and a peak on days 7-10. Although 75% of C3 -/-mice developed arthritis, the clinical severity was very mild and the onset was delayed. Severity of arthritis in FB -/-mice ranked intermediate in comparison with C3 -/-and control mice with an incidence of 100%. Immunohistochemical analysis of the inflamed joints demonstrated substantial reduction in macrophage and neutrophilic leukocyte infiltration in both C3 -/-and FB -/-mice, thereby confirming the clinical findings. We conclude that both the classical and the alternative pathways of complement activation are involved in the effector phase of arthritis.

show abstract

“…Kuhn et al, for example, recently demonstrated that administration of anti-citrullinated fibrinogen antibodies enhanced disease severity in an experimental mouse model of arthritis (4). In the majority of patients with RA, the presence of ACPAs antedates disease onset (5,6), and ACPA-positive patients present with a more severe and erosive form of arthritis (7)(8)(9)(10)(11)(12)(13)(14)(15)(16). A commercial enzyme-linked immunosorbent assay (ELISA) based on cyclic citrullinated peptides (CCPs) detects ACPAs and is now routinely used in the diagnosis of RA.…”

mentioning

confidence: 99%

Antibodies to citrullinated α‐enolase peptide 1 are specific for rheumatoid arthritis and cross‐react with bacterial enolase

Lundberg

Kinloch

Fisher

et al. 2008

Arthritis & Rheumatism

339

313

View full text Add to dashboard Cite

Objective. To map the antibody response to human citrullinated ␣-enolase, a candidate autoantigen in rheumatoid arthritis (RA), and to examine crossreactivity with bacterial enolase.Methods. Serum samples obtained from patients with RA, disease control subjects, and healthy control subjects were tested by enzyme-linked immunosorbent assay (ELISA) for reactivity with citrullinated ␣-enolase peptides. Antibodies specific for the immunodominant epitope were raised in rabbits or were purified from RA sera. Cross-reactivity with other citrullinated epitopes was investigated by inhibition ELISAs, and cross-reactivity with bacterial enolase was investigated by immunoblotting.Results. An immunodominant peptide, citrullinated ␣-enolase peptide 1, was identified. Antibodies to this epitope were observed in 37-62% of sera obtained from patients with RA, 3% of sera obtained from disease control subjects, and 2% of sera obtained from healthy control subjects. Binding was inhibited with homologous peptide but not with the arginine-containing control peptide or with 4 citrullinated peptides from elsewhere on the molecule, indicating that antibody binding was dependent on both citrulline and flanking amino acids. The immunodominant peptide showed 82% homology with enolase from Porphyromonas gingivalis, and the levels of antibodies to citrullinated ␣-enolase peptide 1 correlated with the levels of antibodies to the bacterial peptide (r 2 ‫؍‬ 0.803, P < 0.0001). Affinitypurified antibodies to the human peptide cross-reacted with citrullinated recombinant P gingivalis enolase.Conclusion. We have identified an immunodominant epitope in citrullinated ␣-enolase, to which antibodies are specific for RA. Our data on sequence similarity and cross-reactivity with bacterial enolase may indicate a role for bacterial infection, particularly with P gingivalis, in priming autoimmunity in a subset of patients with RA.

show abstract

The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis

Cited by 546 publications

References 15 publications

The diagnosis and prognosis of early arthritis: Rationale for new prognostic criteria

The diagnosis and prognosis of early arthritis: Rationale for new prognostic criteria

Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis

Antibodies to citrullinated α‐enolase peptide 1 are specific for rheumatoid arthritis and cross‐react with bacterial enolase

Contact Info

Product

Resources

About